Reasons for inclusion

• Male patients over the age of 18 years, presenting with erectile dysfunction

Reasons for exclusion

• All medicines are contraindicated in those who have had hypersensitivity to the active ingredient, or to any of the excipients
• Men for whom sexual activity is inadvisable
• Men who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure
• Severe hepatic impairment
• Men with end stage renal disease requiring dialysis
• Known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases)
• The film coating of the tablet contains lactose. SIldenafil should not be administered to men with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
• Patients with bleeding disorders or active peptic ulceration
• Patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), or patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia)
• Patients using other treatments for erectile dysfunction
• Patients with congenital QT prolongation
• Patients under 18 years of age
• Female
• Cardiovascular disorders, including angina, heart failure, history of stroke and/or myocardial infarction, arrhythmias, hypotension (<90/50mmHg), or hypertension
• These medicines potentiate the hypotensive effects of nitrates, and their co-administration with nitric oxide donors (such as amyl nitrite), or nitrates in any form is therefore contraindicated
• Men taking nicorandil or ritonavir.
• Patients taking the following: – HIV protease inhibitors such as indinavir; – Ketoconazole and itraconazole (oral form); – Grapefruit juice;  – Antiarrhythmics in Class 1A (e.g. quinidine, procainamide), or Class III (e.g. amiodarone, sotalol)
• Orodispersible tablets contain aspartame, a source of phenylalanine which may be harmful for people with phenylketonuria
• Orodispersible tablets contain sorbitol. Patients with rare hereditary problems of fructose intolerance should not take the orodispersible tablets